CA2607185A1 - Intracellular active agents - Google Patents

Intracellular active agents Download PDF

Info

Publication number
CA2607185A1
CA2607185A1 CA002607185A CA2607185A CA2607185A1 CA 2607185 A1 CA2607185 A1 CA 2607185A1 CA 002607185 A CA002607185 A CA 002607185A CA 2607185 A CA2607185 A CA 2607185A CA 2607185 A1 CA2607185 A1 CA 2607185A1
Authority
CA
Canada
Prior art keywords
helix
nucleic acid
section
hmga
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002607185A
Other languages
English (en)
French (fr)
Inventor
Florian Jarosch
Christian Maasch
Sven Klussmann
Axel Vater
Dirk Eulberg
Werner Purschke
Klaus Buchner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2607185A1 publication Critical patent/CA2607185A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
CA002607185A 2005-05-04 2006-05-04 Intracellular active agents Abandoned CA2607185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005020874 2005-05-04
DE102005020874.6 2005-05-04
PCT/EP2006/004180 WO2006117217A2 (de) 2005-05-04 2006-05-04 Neue verwendung von spiegelmeren

Publications (1)

Publication Number Publication Date
CA2607185A1 true CA2607185A1 (en) 2006-11-09

Family

ID=36928624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002607185A Abandoned CA2607185A1 (en) 2005-05-04 2006-05-04 Intracellular active agents

Country Status (11)

Country Link
US (2) US8497250B2 (https=)
EP (2) EP1877069A2 (https=)
JP (2) JP2008540363A (https=)
KR (2) KR101418369B1 (https=)
CN (2) CN101217967B (https=)
AU (1) AU2006243334A1 (https=)
BR (1) BRPI0610367A2 (https=)
CA (1) CA2607185A1 (https=)
MX (1) MX2007013760A (https=)
SG (1) SG161311A1 (https=)
WO (1) WO2006117217A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
WO2011098262A2 (en) * 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP2014533098A (ja) * 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
BR112014016939A2 (pt) * 2012-01-10 2019-09-24 Noxxon Pharma Ag ácidos nucleicos que se ligam especificamente a cgrp
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US9233119B2 (en) * 2012-09-27 2016-01-12 Miami University Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
WO2014193964A2 (en) * 2013-05-28 2014-12-04 Marsha Rosner Prognostic and predictive breast cancer signature
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
KR101755617B1 (ko) 2014-07-23 2017-07-10 한국과학기술연구원 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドKemin Industries, Inc. イオントフォレシスを用いた生物活性分子の眼内送達
US20180153884A1 (en) 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
DE17829597T1 (de) * 2016-11-30 2019-12-05 Noxxon Pharma Ag Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
KR20230005908A (ko) * 2020-04-30 2023-01-10 벨라니디 테크놀로지스 엘엘씨 생물학적 또는 화학적 독립체 또는 이벤트를 검출하기 위한 분자 와이어
CN112725438B (zh) * 2021-02-05 2023-08-22 深圳市宝安区妇幼保健院 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用
CN114807183B (zh) * 2021-12-06 2023-06-02 西藏自治区农牧科学院农业研究所 一种青稞矢车菊素氧甲基转移酶基因的新用途
CN118311277B (zh) * 2024-06-11 2024-12-31 北京卫未科学技术有限公司 一种用于癌症早筛和辅助诊断的试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
JPH09502354A (ja) * 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ,インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
AU728176B2 (en) * 1995-05-04 2001-01-04 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
DE59708838D1 (de) * 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
CN1479632A (zh) * 2000-10-09 2004-03-03 用于将核酸导入细胞的复合物
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
ATE469164T1 (de) * 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
DE50212280D1 (de) * 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
WO2003094973A1 (de) * 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
NZ542687A (en) * 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
AU2004238076A1 (en) * 2003-05-09 2004-11-25 Novosom Ag Injectable liposomal depots for delivering active ingredients
CA2526853A1 (en) * 2003-05-23 2005-03-03 Board Of Regents - The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
JP2007519724A (ja) * 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド 核酸を基剤とする治療剤の制御送達および持続的送達
WO2006069782A2 (en) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use

Also Published As

Publication number Publication date
WO2006117217A2 (de) 2006-11-09
CN101217967A (zh) 2008-07-09
JP5766750B2 (ja) 2015-08-19
EP1877069A2 (de) 2008-01-16
MX2007013760A (es) 2008-01-28
AU2006243334A1 (en) 2006-11-09
WO2006117217A3 (de) 2007-08-09
CN101217967B (zh) 2014-09-10
KR101418369B1 (ko) 2014-07-24
KR20080009276A (ko) 2008-01-28
US9074214B2 (en) 2015-07-07
KR20140042941A (ko) 2014-04-07
EP2206501A3 (de) 2010-09-29
JP2013224319A (ja) 2013-10-31
EP2206501A2 (de) 2010-07-14
SG161311A1 (en) 2010-05-27
US20130337049A1 (en) 2013-12-19
KR101418367B1 (ko) 2014-07-25
CN104293780A (zh) 2015-01-21
US8497250B2 (en) 2013-07-30
JP2008540363A (ja) 2008-11-20
BRPI0610367A2 (pt) 2010-06-15
US20090192100A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US9074214B2 (en) Use of spiegelmers
EP3049523B1 (en) Multiaptamer target detection
Alecki et al. RNA-DNA strand exchange by the Drosophila Polycomb complex PRC2
Tang et al. In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection
Thiviyanathan et al. Aptamers and the next generation of diagnostic reagents
US20060292560A1 (en) Transcription factor target gene discovery
Gunaratne et al. Key RNA-binding domains in the La protein establish tRNA modification levels in Trypanosoma brucei
Clark et al. Activation of human RNA lariat debranching enzyme Dbr1 by binding protein TTDN1 occurs though an intrinsically disordered C-terminal domain
Cho et al. In vitro selection of specific RNA aptamers for the NFAT DNA binding domain
AU2012241062A1 (en) Novel use of spiegelmers
HK1119388A (en) Novel use of spiegelmers
CN116970694B (zh) miR-9及其类似物在制备诊断和/或治疗细胞炎症的药物中的应用
Palchetti et al. Electrochemical nucleic acid aptamer–based biosensors
Faure et al. Cell‐to‐Cell Contact Activates the Long Terminal Repeat of Human Immunodeficiency Virus 1 Through its κB Motif
REGINA STOLTENBURG Development of aptamers as new receptors for environmental biosensors
HK1227430B (en) Multiaptamer target detection
HK1227430A1 (en) Multiaptamer target detection
Xie Aptamers for parallel measurements of cellular molecules
Class et al. Patent application title: Multiaptamer Target Detection Inventors: Urs A. Ochsner (Denver, CO, US) Louis S. Green (Lafayette, CO, US) Larry Gold (Boulder, CO, US) Nebojsa Janjic (Boulder, CO, US) Nebojsa Janjic (Boulder, CO, US) Evaldas Katilius (Superior, AZ, US)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160923